Lifecore Biomedical (LFCR) late Thursday reported a loss of $0.47 per diluted share in fiscal Q3, compared with earnings of $0.42 a share a year earlier.
Two analysts polled by FactSet expected a loss of $0.15.
Revenue for the quarter ended Feb. 23 was $35.2 million, down from $35.7 million a year earlier.
Two analysts surveyed by FactSet expected $33.2 million.
The company reiterated its fiscal 2025 revenue guidance of between $126.5 million and $130.0 million.
Two analysts surveyed by FactSet expected $128.4 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。